India has green-lighted molnupiravir for restricted emergency use in COVID-19, paving the way for the arrival of around a dozen generic versions of Merck & Co., Inc. and Ridgeback Biotherapeutics LP ‘s oral antiviral therapy in the country.
Front-line Indian firms in the fray are upbeat about potential opportunities for molnupiravir, though much will depend on the trajectory...







